METTL3 and breast cancer: Altogether, these findings indicate that the METTL3-lncRNAKCNQ1OT1/ miR-103a-3p-MDR1 axis is responsible for ADR resistance in BC, which suggests a novel approach to prevent ADR resistance in patients with BC.